Summer Sale

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Publisher
source

Ruben ArteroRuben Artero

1 year ago

Oligonucleotide-based therapies for myotonic dystrophy University of Valencia in Spain

Degree Level

PhD

Field of study

Neuroscience

Funding

Full funding available

Deadline

Expired

Country flag

Country

Spain

University

University of Valencia

Social connections

How do I apply for this?

Sign in for free to reveal details, requirements, and source links.

More information can be found here

Official Email

[email protected]

Keywords

Neuroscience
Cell Biology
Physiology
Molecular Biology
Biomedical Engineering
Biology
Rna Biology
Neuropsychology
Biopharmaceutics
Omics
Genomic
Rna Therapeutics
Muscular Atrophy
Biomedicine
msc

About this position

?? Job Alert! ??

Join our ambitious Marie Sklodowska-Curie Doctoral Network and be part of a cutting-edge European research consortium! This is a unique opportunity to receive topr training, work with leading experts, and contribute to an innovative project.

?? Don’t miss out—apply now and take your research career to the next level!

PhDOpportunity MarieCurie ResearchExcellence DoctoralTraining JoinUs
We participate in ENTRY-DM, an MSCA multidisciplinary doctoral network aimed at developing oligonucleotide-based therapies and preparing clinical trials in myotonic dystrophy, through advanced doctoral training. It brings together 11 European laboratories and 18 international partners with expertise in disciplines as varied as medicinal chemistry, genetics, multi-omics, bioengineering and neuropsychology. The network is recruiting 14 doctoral candidates through Euraxess under the leadership of Mario Gomes-Pereira. Within the network, our laboratory is seeking two Doctoral Candidates (DC) who will enjoy a dynamic environment at the University of Valencia and close contact with ARTHEX Biotech, a spin-off company from our laboratory.
DC6 will focus on understanding the mechanisms by which MBNL translational repressor miRNAs are misregulated in DM1, their contribution to the disease, and how DMPK levels change in response to antimiRs. You will use muscle models such as immortalized patient-derived cells and human primary myoblasts.
DC9 will aim to discover means to enhance therapeutic antisense oligonucleotides by improving cellular uptake and endosomal escape, including genetic and drug screens using reporter cell lines. Effective approaches will be prioritized, and mechanisms of action will be defined. Results will be validated in DM1 disease models, evaluating hallmark features like RNA foci, and muscle strength using patient-derived cells and transgenic mice.
Candidate Profile: We seek a highly motivated and ambitious candidate with a strong background in genetics and cellular biology, particularly in RNA-based therapeutics. The ideal candidate should hold a Master’s degree in Molecular Life Sciences, Physiology, Biomedical Sciences, or a related field, with hands-on experience in gene and protein quantification techniques, immunofluorescence, and cell culturing.
Application Process (before deadline May 30th): Submit a single PDF document to Ruben Artero (DC6; [email protected] ), or Arturo López Castel (DC9; [email protected] ), and [email protected] , including your CV, motivation letter, academic certificates, proof of English proficiency, national identity card, and two recommendation letters.

Funding details

Full funding including tuition fees and living expenses is available for this position. The scholarship covers all educational costs and provides a monthly stipend.

How to apply

Please submit your application including a cover letter, CV, academic transcripts, and contact information for two references. Applications should be sent via the online portal before the deadline.

Ask ApplyKite AI

Start chatting
Can you summarize this position?
What qualifications are required for this position?
How should I prepare my application?

Professors